Biotech Values

[ariadndndough]

kris kade you see this investorvillage post on acad

http://www.investorvillage.com/smbd.asp?mb=523&mn=864&pt=msg&mid=13929508

Better with Time
If you go to the link below you'll see the Lancet paper with 6 graphs showing pima's sig stat effect in the P3 PDP trial. Those graphs over 6 weeks show not only that Pima had a good effect but that effect in each test but one appeared to get better over the last 2 weeks. The ongoing ADP trial will have 6 week and 12 week scores so if the improving trend continues then the ADP could show better numbers than the PDP patients. 12 weeks is also the minimum needed to show a difference in cognition scales. I think ACAD hopes to show patients on Pima don't deteriorate as fast as placebos. The current antipsychotics appear to worsen dementia for some of these patients. The only drug class that can slow dementia's progress are the acetylcholinesterase inhibitors like Aricept. They tend to help for about 6 months. But several papers have been published showing that less sleep and more psychosis leads to more dementia. Since Pima improves both I think there is a decent chance Pima could also slow the cognitive loss seen in ADP.

http://digitalreprints.elsevier.com/i/209565/2
(hit graphs to enlarge)